Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rockwell Medical (RMTI) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Rockwell Medical (RMTI) over the last 17 years, with Q3 2025 value amounting to $1.5 million.

  • Rockwell Medical's Accounts Payables fell 4158.04% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year decrease of 4158.04%. This contributed to the annual value of $2.9 million for FY2024, which is 3647.03% down from last year.
  • Rockwell Medical's Accounts Payables amounted to $1.5 million in Q3 2025, which was down 4158.04% from $1.5 million recorded in Q2 2025.
  • Over the past 5 years, Rockwell Medical's Accounts Payables peaked at $5.9 million during Q2 2023, and registered a low of $1.5 million during Q2 2025.
  • Moreover, its 5-year median value for Accounts Payables was $3.7 million (2021), whereas its average is $3.6 million.
  • Its Accounts Payables has fluctuated over the past 5 years, first soared by 10146.16% in 2023, then tumbled by 6086.6% in 2025.
  • Quarter analysis of 5 years shows Rockwell Medical's Accounts Payables stood at $3.7 million in 2021, then rose by 8.4% to $4.1 million in 2022, then grew by 11.42% to $4.5 million in 2023, then plummeted by 36.47% to $2.9 million in 2024, then crashed by 46.92% to $1.5 million in 2025.
  • Its Accounts Payables stands at $1.5 million for Q3 2025, versus $1.5 million for Q2 2025 and $1.9 million for Q1 2025.